Myopia is generally what happens when unprecedented opportunities are placed before them. Those in the know generally do better than those in the worry. Consider Cetus, a startup biotech with a focus on a liver drug. The FDA delayed the approval of the drug, and a major funding crisis ensued. Chiron offered to take over the liabilities contingent on the sale of two patents (# 4,683,202 and # 4,683,195) to a third party, Roche Molecule for $300M (in 1993). This sale was stalled because DuPont challenged the validity of the patents, based on the formal claims written by the inventor (not a patent attorney), Kary Mullis. In the end, the soap opera turned out well for the investors with weak constitutions. For $300M, they sold the two patents to Roche, turned the company over to Chiron, and walked away. Kary Mullis won the Nobel prize for his invention embedded in these two patents, known as polymerase chain reaction (PCR) which allows DNA to be cloned. Over 4000 patents in biotech cite these original two patents. In our estimation, $300M represents "pennies on the dollar" valuation of these patents. The shareholders got a payday, and left the game. Roche on the other hand is thriving based on its intangible assets. Let IPstreet.com assist you.
IP Street takes know-how and confidence when helping you manage your IP assets. We help you better understand the duration of a patent, the value of a patent and patent analytics.
Resources are limited. Which patents should we maintain? Should we maintain international fees? Which patents pay the best royalties? Such questions are essential to perform IP audits consistently. A major limitation to make this happen is the lack of organization. With IP Street, we can help you quickly and easily search your universe of patents to get your 'House in Order.' Our patent search tools will assist you significantly.
Patents have a maximum life of 20 years and, therefore, a 20-year potential monopoly. Patents that are just beginning their life and which have longer to run on the their potential monopoly position understandably will have more value. It is rare that a patent nearing the end of its term will cause a great threat to its competitors. It is almost certain that they will have devised technologies or products of their own by then that will not interfere with the patent owners monopoly position. In addition, one has to take into consideration the potential business life of a patent, i.e., the duration, which a patent is likely to be economically useful, if other subsequent patents are providing better alternatives to it.
Managing human capital is fundamental for a company's success. Merged with IP capital, a new realm of Intellectual Capital needs to be carefully considered. Alone, patents and inventors are important. But together, their synergies may be invaluable to a firm. Know which patents matter, which inventors matter, and which inventors play nice together. Whether you are searching to hire a new inventor, wanting to monitor inventor productivity, or want to analyze your inventor networks (relationships among inventors), IP Street simplifies the complex to provide meaningful insights.
(20) Words.
